<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03440112</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00360361-A</org_study_id>
    <secondary_id>R01NS099535</secondary_id>
    <nct_id>NCT03440112</nct_id>
  </id_info>
  <brief_title>Modulation of GABA-A Receptors in Parkinson Disease-Transdermal Flumazenil Arm</brief_title>
  <acronym>GABA-A</acronym>
  <official_title>Modulation of GABA-A Receptors and Axial Motor Impairments in Parkinson</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nicolaas Bohnen, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The arm of this study evaluates possible GABA-A receptor target engagement effects of the&#xD;
      FDA-approved medication, transdermal flumazenil (added 4/2020, replaced clarithromycin), in&#xD;
      the setting of Parkinson's disease. Half of the subjects will receive transdermal flumazenil&#xD;
      for 7-10 days, and half will receive a placebo. [11C]Flumazenil GABA-A receptor PET imaging&#xD;
      will be used to assess target engagement effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study focuses on neurochemical changes in the brain that occur in Parkinson's disease.&#xD;
      In particular we will be looking a neurotransmitter called GABA. In some Parkinson's disease&#xD;
      patients we see too much GABA activity in the brain. This target engagement study examines&#xD;
      the target engagement effect of GABA-A receptor modulation by transdermal flumazenil&#xD;
      (previously clarithromycin). [11C]-flumazenil Positron Emission Tomography (PET) imaging&#xD;
      results will be used to assess for possible GABA-A receptor target engagement effects of&#xD;
      transdermal flumazenil (previously clarithromycin).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Participant, Investigator</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in quantitative biomechanics 1</measure>
    <time_frame>7-10 days</time_frame>
    <description>We will use the total MDS-UPDRS motor scale to assess motor functions before and after 7 days of transdermal flumazenil</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in quantitative biomechanics 2</measure>
    <time_frame>7-10 days</time_frame>
    <description>We will use the PIGD-UPDRS motor scale to assess axial motor functions before and after 7 days of transdermal flumazenil</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Clarithromycin (Not used anymore as of 4/2020)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clarithromycin 250mg (1 capsule) will be taken orally twice a day for 3 days and if tolerated will be increased to 500mg (2 capsules) orally twice a day for 4-6 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Not used anymore as of 4/2020)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be taken exactly as the clarithromycin arm: 1 capsule orally twice a day for 3 days and if tolerated will be increased to 2 capsules orally twice a day for 4-6 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transdermal flumazenil (added 4/2020)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Added in April 2020. Subjects will take 18mg transdermal application every 3-4 hrs dispensed as 3 dispenser bottle clicks of 0.25 ml each, while awake for 3 days then if no side-effects subjects will increase to 36mg transdermal application every 3-4 hrs dispensed as 6 dispenser bottle clicks of 0.25 ml each, while awake.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo cream (added 4/2020)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Added in April 2020. Placebo will be taken exactly as the transdermal flumazenil arm: Subjects will take 18mg transdermal application every 3-4 hrs dispensed as 3 dispenser bottle clicks of 0.25 ml each, while awake for 3 days then if no side-effects subjects will increase to 36mg transdermal application every 3-4 hrs dispensed as 6 dispenser bottle clicks of 0.25 ml each, while awake.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin (Not used as of 4/2020)</intervention_name>
    <description>Clarithromycin (generic) capsule 250mg each</description>
    <arm_group_label>Clarithromycin (Not used anymore as of 4/2020)</arm_group_label>
    <other_name>Biaxin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Not used as of 4/2020)</intervention_name>
    <description>Lactose in a gel capsule</description>
    <arm_group_label>Placebo (Not used anymore as of 4/2020)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transdermal flumazenil (Added 4/2020)</intervention_name>
    <description>Transdermal flumazenil 24mg/mL</description>
    <arm_group_label>Transdermal flumazenil (added 4/2020)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Added 4/2020)</intervention_name>
    <description>Transdermal placebo</description>
    <arm_group_label>Placebo cream (added 4/2020)</arm_group_label>
    <other_name>Placebo cream</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Parkinson's disease (PD): PD diagnosis will follow the UK Parkinson's Disease Society&#xD;
             Brain Bank Research Center (UKPDSBRC) clinical diagnostic criteria for PD.&#xD;
&#xD;
          2. Hoehn and Yahr stages 2-4&#xD;
&#xD;
          3. Absence of dementia confirmed by cognitive testing.&#xD;
&#xD;
          4. Abnormal 11C-Dihydrotetrabenazine ([11c]-DTBZ) PET study to demonstrate nigrostriatal&#xD;
             dopaminergic denervation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. PD with Dementia (PDD) or dementia with Lewy bodies (DLB).&#xD;
&#xD;
          2. Other disorders which may resemble PD, such as vascu¬lar dementia, normal pressure&#xD;
             hydrocephalus, multiple system atrophy, corticobasal ganglionic dege¬neration, or&#xD;
             toxic causes of parkinsonism. Prototypical cases have distincti¬ve clinical profiles,&#xD;
             like early and severe dysautonomia or appendicular apraxia, which may differentiate&#xD;
             them from idiopathic PD. The use of the UKPDSBRC clinical diagnostic criteria for PD&#xD;
             will mitigate the inclusion of subjects with atypical parkinsonism.&#xD;
&#xD;
          3. Subjects currently on benzodiazepine, GABAB-ergic medications (baclofen, tizanidine),&#xD;
             modafinil, neuroleptic, anticholinergic (trihexyphenidyl, benztropine), or&#xD;
             cholinesterase inhibitor drugs.&#xD;
&#xD;
          4. Evidence of a mass lesion on structural brain imaging (MRI).&#xD;
&#xD;
          5. Participants in whom MRI is contraindicated including, but not limited to, those with&#xD;
             a pacemaker, presence of metallic fragments near the eyes or spinal cord, chest, or&#xD;
             cochlear implant.&#xD;
&#xD;
          6. Severe claustrophobia precluding MR or PET imaging.&#xD;
&#xD;
          7. Subjects limited by participation in research procedures involving ionizing radiation.&#xD;
&#xD;
          8. Pregnancy (urine or serum pregnancy test within 48 hours of each PET session) or&#xD;
             breastfeeding.&#xD;
&#xD;
          9. History of seizures&#xD;
&#xD;
         10. Significant anxiety or history of panic disorder.&#xD;
&#xD;
         11. History of recent suicide attempt or overdose of tricyclic antidepressants or other&#xD;
             medications.&#xD;
&#xD;
         12. History of transient ischemic attack (TIA) or stroke within the last year.&#xD;
&#xD;
         13. History of systemic lupus erythematosis.&#xD;
&#xD;
         14. Abnormal liver enzymes (AST or ALT) &gt; 3 times upper limit of normal.&#xD;
&#xD;
         15. History of atrial fibrillation.&#xD;
&#xD;
         16. History of retinal branch artery occlusion.&#xD;
&#xD;
         17. Active dermatitis inner forearms.&#xD;
&#xD;
         18. Any other medical history determined by investigators to preclude safe participation.&#xD;
&#xD;
        Additional Exclusion Criteria for Flumazenil sub-studies:&#xD;
&#xD;
          1. Allergy to flumazenil&#xD;
&#xD;
          2. Significant liver disease&#xD;
&#xD;
          3. History of alcohol or other substance abuse within past two years.&#xD;
&#xD;
          4. Subjects currently taking benzodiazepines&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolaas I Bohnen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolaas Bohnen</last_name>
    <phone>734-998-8400</phone>
    <email>nbohnen@umich.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sheryl Korsnes</last_name>
    <phone>734-998-8400</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Michigan Health System Functional Neuroimaging, Cognitive and Mobility Laboratory</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolaas Bohnen</last_name>
      <phone>734-998-8400</phone>
      <email>nbohnen@umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sheryl Korsnes</last_name>
      <phone>734-998-8400</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 26, 2018</study_first_submitted>
  <study_first_submitted_qc>February 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2018</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Nicolaas Bohnen, MD, PhD</investigator_full_name>
    <investigator_title>Professor of Radiology and Neurology</investigator_title>
  </responsible_party>
  <keyword>Gait</keyword>
  <keyword>Balance</keyword>
  <keyword>GABA</keyword>
  <keyword>Transdermal flumazenil (previously Clarithromycin changed 4/2020)</keyword>
  <keyword>PET Imaging</keyword>
  <keyword>MRI</keyword>
  <keyword>Mobility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Flumazenil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

